CAR--话题@MedSci - williamhill asia

#CAR-#

460篇内容 | 3904人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781084, encodeId=061c1e81084b5, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=J Immunol：CAR-T和TCR-T的前景与挑战, objectType=article, longId=55610, objectId=a6b655610ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6b655610ca, replyNumber=0, likeNumber=81, createdTime=2016-02-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6b655610ca, moduleTitle=J Immunol：CAR-T和TCR-T的前景与挑战, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=a6b655610ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781092, encodeId=85401e8109253, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T与溶瘤病毒的联合使用, objectType=article, longId=59454, objectId=39ce5945449, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39ce5945449, replyNumber=0, likeNumber=106, createdTime=2016-09-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39ce5945449, moduleTitle=CAR-T与溶瘤病毒的联合使用, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=39ce5945449)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781081, encodeId=978e1e8108176, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=ASCO 2015：CAR-T治疗药物CTL019难治性非霍奇金淋巴瘤疗效潜力惊人, objectType=article, longId=52319, objectId=65185231966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65185231966, replyNumber=0, likeNumber=123, createdTime=2015-09-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65185231966, moduleTitle=ASCO 2015：CAR-T治疗药物CTL019难治性非霍奇金淋巴瘤疗效潜力惊人, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=65185231966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781079, encodeId=89eb1e81079c0, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=深度完整版：CAR-T的现状和未来, objectType=article, longId=51212, objectId=c615512129b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c615512129b, replyNumber=0, likeNumber=106, createdTime=2016-04-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c615512129b, moduleTitle=深度完整版：CAR-T的现状和未来, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c615512129b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781087, encodeId=b00d1e8108770, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Science：新型分子开关型CAR-T系统，助力精准免疫治疗, objectType=article, longId=56645, objectId=d3025664593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3025664593, replyNumber=0, likeNumber=97, createdTime=2016-02-05, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3025664593, moduleTitle=Science：新型分子开关型CAR-T系统，助力精准免疫治疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d3025664593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781080, encodeId=7be81e8108098, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=解放军总医院发布CAR-T疗法 I期临床数据, objectType=article, longId=51284, objectId=2f8e51284f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f8e51284f2, replyNumber=0, likeNumber=108, createdTime=2015-08-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f8e51284f2, moduleTitle=解放军总医院发布CAR-T疗法 I期临床数据, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2f8e51284f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781089, encodeId=18c31e810897b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=NEJM：CAR-T细胞治疗多发性骨髓瘤获得完全缓解, objectType=article, longId=56743, objectId=8f5f56e432e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f5f56e432e, replyNumber=0, likeNumber=84, createdTime=2016-02-03, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f5f56e432e, moduleTitle=NEJM：CAR-T细胞治疗多发性骨髓瘤获得完全缓解, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=8f5f56e432e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781083, encodeId=d4bd1e81083fe, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T和TCR-T 在肿瘤领域应用前景和挑战, objectType=article, longId=54072, objectId=d61a540e292, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d61a540e292, replyNumber=0, likeNumber=103, createdTime=2015-08-04, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d61a540e292, moduleTitle=CAR-T和TCR-T 在肿瘤领域应用前景和挑战, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d61a540e292)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781077, encodeId=6a0c1e8107761, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=MedImmune携手Juno！CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章？！, objectType=article, longId=49896, objectId=41ff498968d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ff498968d, replyNumber=0, likeNumber=82, createdTime=2015-10-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ff498968d, moduleTitle=MedImmune携手Juno！CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章？！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=41ff498968d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781090, encodeId=cc1b1e810909f, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=同种异体来源的CAR-T机遇与挑战, objectType=article, longId=57259, objectId=106b5e259a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=106b5e259a2, replyNumber=0, likeNumber=101, createdTime=2016-05-24, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=106b5e259a2, moduleTitle=同种异体来源的CAR-T机遇与挑战, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=106b5e259a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781074, encodeId=5eea1e810740d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T疗法扩展：Unum Therapeutic招募一期临床病人, objectType=article, longId=43480, objectId=00244348054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00244348054, replyNumber=0, likeNumber=90, createdTime=2015-09-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00244348054, moduleTitle=CAR-T疗法扩展：Unum Therapeutic招募一期临床病人, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=00244348054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781082, encodeId=9b6f1e8108209, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=ASCO 2015：CAR-T细胞疗法正在攻克实体瘤胰腺癌是初露曙光, objectType=article, longId=52363, objectId=e3d552363ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3d552363ff, replyNumber=0, likeNumber=119, createdTime=2015-10-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3d552363ff, moduleTitle=ASCO 2015：CAR-T细胞疗法正在攻克实体瘤胰腺癌是初露曙光, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e3d552363ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781076, encodeId=fd211e81076d0, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=1亿美金，Intrexon与Ziopharm为CAR-T研究再添一把火！, objectType=article, longId=45581, objectId=bfa4455816f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfa4455816f, replyNumber=0, likeNumber=80, createdTime=2015-10-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfa4455816f, moduleTitle=1亿美金，Intrexon与Ziopharm为CAR-T研究再添一把火！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=bfa4455816f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781075, encodeId=3a671e810756d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=ASH 2014：CAR-T免疫疗法治疗难治性ALL缓解率达92%, objectType=article, longId=44389, objectId=48f34438970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48f34438970, replyNumber=0, likeNumber=100, createdTime=2015-06-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48f34438970, moduleTitle=ASH 2014：CAR-T免疫疗法治疗难治性ALL缓解率达92%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=48f34438970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781078, encodeId=1e0b1e810789d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Car-T治疗实体肉瘤：细胞存活超过六周且无明显毒性反应, objectType=article, longId=51043, objectId=7d3d5104344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d3d5104344, replyNumber=0, likeNumber=139, createdTime=2015-05-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d3d5104344, moduleTitle=Car-T治疗实体肉瘤：细胞存活超过六周且无明显毒性反应, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7d3d5104344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781072, encodeId=1adf1e81072bc, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=竞争白热化！强生与Transposagen签订合作协议宣布进入CAR-T研究领域, objectType=article, longId=43155, objectId=ea2343155b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea2343155b0, replyNumber=0, likeNumber=89, createdTime=2015-10-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea2343155b0, moduleTitle=竞争白热化！强生与Transposagen签订合作协议宣布进入CAR-T研究领域, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ea2343155b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781071, encodeId=7c961e8107136, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T免疫疗法，治愈癌症不是梦, objectType=article, longId=43115, objectId=49b74311597, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49b74311597, replyNumber=0, likeNumber=94, createdTime=2015-07-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49b74311597, moduleTitle=CAR-T免疫疗法，治愈癌症不是梦, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=49b74311597)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781070, encodeId=ad401e8107048, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=诺华CAR-T疗法获得FDA突破性疗法认证, objectType=article, longId=37655, objectId=60823e6550d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60823e6550d, replyNumber=0, likeNumber=89, createdTime=2015-04-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60823e6550d, moduleTitle=诺华CAR-T疗法获得FDA突破性疗法认证, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=60823e6550d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781073, encodeId=f31d1e8107369, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=肿瘤Car-T免疫细胞治疗JCAR015获FDA突破性疗法认定, objectType=article, longId=43164, objectId=fe944316495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe944316495, replyNumber=0, likeNumber=92, createdTime=2015-05-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe944316495, moduleTitle=肿瘤Car-T免疫细胞治疗JCAR015获FDA突破性疗法认定, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fe944316495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781069, encodeId=2bfd1e8106963, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T细胞治疗非霍奇金氏淋巴瘤经历“阿喀琉斯之踵”, objectType=article, longId=34176, objectId=dd6a341e6fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd6a341e6fe, replyNumber=0, likeNumber=110, createdTime=2014-11-21, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd6a341e6fe, moduleTitle=CAR-T细胞治疗非霍奇金氏淋巴瘤经历“阿喀琉斯之踵”, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=dd6a341e6fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

CAR-

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

J Immunol：CAR-T和TCR-T的前景与挑战

2016-02-02

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T与溶瘤病毒的联合使用

2016-09-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

ASCO 2015：CAR-T治疗药物CTL019难治性非霍奇金淋巴瘤疗效潜力惊人

2015-09-13

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

深度完整版：CAR-T的现状和未来

2016-04-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Science：新型分子开关型CAR-T系统，助力精准免疫治疗

2016-02-05

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

解放军总医院发布CAR-T疗法 I期临床数据

2015-08-27

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

NEJM：CAR-T细胞治疗多发性骨髓瘤获得完全缓解

2016-02-03

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T和TCR-T 在肿瘤领域应用前景和挑战

2015-08-04

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

MedImmune携手Juno！CAR-T疗法与PD-L1疗法联合将开启肿瘤免疫新篇章？！

2015-10-11

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

同种异体来源的CAR-T机遇与挑战

2016-05-24

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T疗法扩展：Unum Therapeutic招募一期临床病人

2015-09-20

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

ASCO 2015：CAR-T细胞疗法正在攻克实体瘤胰腺癌是初露曙光

2015-10-13

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

1亿美金，Intrexon与Ziopharm为CAR-T研究再添一把火！

2015-10-17

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

ASH 2014：CAR-T免疫疗法治疗难治性ALL缓解率达92%

2015-06-11

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Car-T治疗实体肉瘤：细胞存活超过六周且无明显毒性反应

2015-05-26

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

竞争白热化！强生与Transposagen签订合作协议宣布进入CAR-T研究领域

2015-10-12

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T免疫疗法，治愈癌症不是梦

2015-07-12

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

诺华CAR-T疗法获得FDA突破性疗法认证

2015-04-28

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

肿瘤Car-T免疫细胞治疗JCAR015获FDA突破性疗法认定

2015-05-12

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T细胞治疗非霍奇金氏淋巴瘤经历“阿喀琉斯之踵”

2014-11-21

科室
- - 订阅+
  - 更多科室
工具
服务